Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.49 |
| ▸ | ESR1 | P03372 | 2/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.47 |
| ▸ | HPGD | P15428 | 6/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | CASP1 | P29466 | 4/20 | 0.47 |
| ▸ | CASP7 | P55210 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | SRC | P12931 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3994327 | 0.80 | SRC (0.64) | HSD17B3KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL14384569 | 0.75 | CYP2C9 (0.70) | CYP2C9HSD17B3ESR1ARKDM4E | |
| SCHEMBL15161176 | 0.74 | AR (0.47) | CYP2C9ARKDM4EALDH1A1MAPT | |
| SCHEMBL27457481 | 0.72 | KDM4E (0.50) | CYP2C9HSD17B3ESR1ARKDM4E | |
| SCHEMBL5273533 | 0.72 | CYP2C9 (1.00) | CYP2C9HSD17B3ESR1ARKDM4E | |
| SCHEMBL5284518 | 0.70 | KDM4E (0.60) | CYP2C9HSD17B3ESR1ARKDM4E | |
| SCHEMBL5905798 | 0.70 | CYP2C9 (0.79) | CYP2C9HSD17B3ESR1ARKDM4E | |
| SCHEMBL31415321 | 0.70 | LCK (0.55) | HSD17B3KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL180110 | 0.70 | LCK (0.55) | HSD17B3KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL29752815 | 0.69 | SRC (0.64) | HSD17B3KDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280856-A1 | Fibroblast Activation Protein Inhibitor Compounds and Methods | GENENTECH, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| EP-1943257-A2 | FIBROBLAST ACTIVATION PROTEIN INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| US-7399869-B2 | N-blocked peptide proline boronate compounds; hyperproliferative disorders like cancer, neurodegeneration, cardiac hypertrophy, pain, migraine, neurotraumatic disease, cirrhosis, fibromatosis, and rheumatoid arthritis | GENENTECH, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-20060276435-A1 | Fibroblast activation protein inhibitor compounds and methods | GENENTECH, INC. (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006125227-A2 | FIBROBLAST ACTIVATION PROTEIN INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276435-A1 | Fibroblast activation protein inhibitor compounds and methods | FAP, FIBP, FGFR1 | CYP2C9 4510/4885HSD17B3 3802/4885ESR1 4234/4885 |
| US-20080280856-A1 | Fibroblast Activation Protein Inhibitor Compounds and Methods | FAP, FIBP, FGFR1 | CYP2C9 4510/4885HSD17B3 3802/4885ESR1 4234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.